Alpha-lipoic acid (ALA) is a naturally occurring compound essential for mitochondrial enzyme complexes, particularly those involved in the citric acid cycle, which is crucial for cellular energy production.
As a cofactor for enzymes like pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, ALA plays a pivotal role in mitochondrial metabolism.
Deficiencies in ALA synthesis or attachment, due to genetic mutations, can lead to severe mitochondrial diseases marked by respiratory deficiency, muscle weakness, and neurological impairments.
ALA is also a potent antioxidant, combating oxidative stress by scavenging free radicals and protecting cells from damage. Its therapeutic potential extends to conditions such as diabetes, metabolic disorders, and neurodegenerative diseases, where it improves insulin sensitivity, reduces oxidative stress, and enhances mitochondrial function.
Despite its benefits, high doses of ALA may pose risks, highlighting the need for careful consideration in therapeutic applications.
Alpha-lipoic acid (ALA) is a naturally occurring compound that is a cofactor for mitochondrial enzyme complexes, particularly those involved in the citric acid cycle, which is crucial for producing cellular energy.
Alpha-lipoic acid (ALA) plays a crucial role in mitochondrial metabolism as an enzyme cofactor, essential for the function of several mitochondrial enzyme complexes, including pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase.
Defects in the synthesis and attachment of ALA, due to mutations in genes like LIAS, LIPT1, and LIPT2, lead to severe mitochondrial diseases characterized by respiratory deficiency, muscle weakness, and neurological impairments.
Recent biochemical data elucidate a pathway where ALA is assembled and transferred onto its cognate enzymes, highlighting the vital role of enzymes like LIPT1 in this process.
However, supplementation with ALA has not proven effective in reversing these genetic defects, indicating the complexity of these metabolic pathways and the challenges in developing therapeutic strategies.
One of the critical functions of lipoic acid is its role in combating oxidative stress.
Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the body's ability to neutralize these harmful compounds.
Lipoic acid helps mitigate oxidative stress by acting as an antioxidant, scavenging free radicals, and reducing the damage they can cause to cells and tissues. This antioxidant action of lipoic acid is particularly vital in preventing cellular damage and maintaining the integrity of mitochondrial and cellular functions.
In certain mitochondrial diseases, mutations in the genes responsible for lipoic acid metabolism, such as LIAS, LIPT1, and LIPT2, can lead to defective lipoic acid synthesis and attachment.
These genetic defects result in severe metabolic disruptions, including impaired respiration, accumulation of toxic metabolites, and significant oxidative damage.
The inability to properly synthesize and utilize lipoic acid in these conditions underscores its importance in maintaining cellular health and preventing oxidative stress-related damage.
Lipoic acid has emerged as a promising biomarker due to its altered levels observed in various pathological conditions, particularly those associated with mitochondrial dysfunction and oxidative stress.
Alpha-lipoic acid (ALA) is a natural compound with antioxidant properties, widely used for its beneficial effects on insulin sensitivity and diabetic polyneuropathy.
ALA helps improve nerve conduction and alleviate symptoms in diabetic neuropathy.
It is also prescribed for other insulin-resistant conditions such as metabolic syndrome, polycystic ovary syndrome (PCOS), and obesity. [3.]
ALA influences glucose metabolism by enhancing insulin sensitivity and secretion, reducing circulating lipid levels, and increasing nitric oxide. [3.]
It acts as a metal chelator and regenerates endogenous antioxidants like vitamins C and E.
Moreover, ALA has been shown to improve glucose uptake, particularly in muscle cells, by activating pathways that enhance insulin receptor activity and GLUT4 translocation. [3.]
In diabetic neuropathy, ALA significantly improves symptoms and nerve conduction. It works as both a direct and indirect antioxidant, scavenging free radicals and increasing intracellular antioxidant levels. [3.]
However, high doses of ALA may exacerbate inflammation and oxidation in diabetic patients.
Another study indicated that lipoic acid increased the formation of methaemoglobin, a form of oxidized hemoglobin, in erythrocytes. [4.]
This effect was more pronounced in diabetic cells compared to non-diabetic ones, highlighting the potential risk of oxidative damage in diabetic patients when exposed to high doses of lipoic acid, especially under conditions of low glucose availability. [4.]
Mitochondrial diseases are genetic disorders that impair the mitochondrial oxidative phosphorylation system, leading to insufficient energy production in high-demand organs such as the nervous system, muscles, and heart.
Despite advancements in understanding these diseases, treatments remain mostly symptomatic and do not significantly change disease progression. Among the therapies being evaluated is alpha-lipoic acid (ALA), due to its role as an antioxidant and cofactor for at least two mitochondrial enzymes.
ALA acts as a potent antioxidant, reducing oxidative stress by scavenging free radicals and reactive oxygen species (ROS).
This is crucial in mitochondrial disorders, where excessive ROS production can further damage cellular structures. By decreasing oxidative stress markers, ALA helps protect against cellular damage.
ALA is often administered alongside other antioxidants to enhance its effects. Studies have shown that a combination of ALA, creatine, and CoQ10 can lower lactate levels and oxidative stress markers, as well as mitigate muscle strength decline in individuals with mitochondrial diseases. Usual doses range from 300 to 600 mg/day for adults. [6.]
Alpha-Lipoic Acid (ALA) has potential in treating neurodegenerative disorders.
ALA's unique properties allow it to cross the blood-brain barrier, acting in both the cytosol and plasma membrane.
Its antioxidant activity inhibits reactive oxygen species (ROS) formation and neuronal damage while promoting antioxidant levels and reducing oxidative stress.
Additionally, ALA enhances mitochondrial biogenesis and function, which is crucial as mitochondrial dysfunction is a hallmark of many neurodegenerative diseases.
ALA also influences genes encoding Nrf-2 and NF-κB, modulating inflammatory responses and promoting neuroprotection. Moreover, it interacts with second messengers like cAMP, affecting pathways involved in inflammation and cellular stress responses.
The clinical implications of ALA are significant, given its ability to improve mitochondrial function and its antioxidant properties. In Parkinson's Disease (PD), ALA protects dopaminergic neurons from oxidative stress and mitochondrial dysfunction, potentially altering disease progression.
In Alzheimer's Disease (AD), it mitigates cognitive dysfunction by enhancing mitochondrial function and reducing oxidative stress, which are key factors in AD pathology.
For Multiple Sclerosis (MS), ALA's anti-inflammatory and neuroprotective effects help manage the inflammatory and degenerative processes characteristic of the disease.
Additionally, in the context of stroke, ALA reduces oxidative damage and promotes recovery following ischemic events, partly through the Nrf2/HO-1 pathway.
Lipoic acid can be measured in blood. Sample collection requires a venipuncture.
It is important to consult the ordering provider prior to sample collection. Special preparation, including fasting or adjustments to supplement dosing, may be required.
Lipoic acid confers multiple benefits to promote mitochondrial health and protect against oxidative stress.
One laboratory company utilizes whole blood samples to assess an individual’s resistance to oxidative stress. They report optimal levels as being >/= 120% protection against oxidative stress. [8.]
Higher levels of lipoic acid generally indicate increased protection against oxidative stress.
Lower levels of lipoic acid may indicate a decreased level of protection against oxidative stress. In this setting, test results should be interpreted according to an individual’s comprehensive clinical picture.
Further testing for other antioxidants, as well as markers of oxidative stress, should be considered.
In addition to lipoic acid, several other biomarkers can provide complementary information about oxidative stress, mitochondrial function, and metabolic pathways related to lipoic acid's roles in the body.
Acylcarnitines and organic acids are markers of fatty acid oxidation disorders, which are closely linked to mitochondrial function and energy metabolism.
Lipoic acid serves as a cofactor for enzymes involved in these pathways.
Measuring acylcarnitine and organic acid profiles can provide insights into the overall status of fatty acid oxidation and related metabolic processes.
Lipoic acid is a potent antioxidant, and its levels may correlate with other markers of oxidative stress.
These include malondialdehyde (a product of lipid peroxidation) and isoprostanes. [1., 2.]
Assessing these markers alongside lipoic acid can provide a more comprehensive picture of the body's redox status and oxidative damage.
Oxidative stress and inflammation are closely interrelated processes.
Measuring inflammatory markers such as C-reactive protein (CRP), high-sensitivity CRP, and cytokines (e.g., interleukin-6, tumor necrosis factor-alpha) can complement lipoic acid levels in conditions where both oxidative stress and inflammation play a role, such as metabolic disorders and neurodegenerative diseases.
Click here to compare testing options and order testing for lipoic acid.
[1.] Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014;2014:360438. doi: 10.1155/2014/360438. Epub 2014 May 8. PMID: 24999379; PMCID: PMC4066722.
[2.] Bauer J, Ripperger A, Frantz S, Ergün S, Schwedhelm E, Benndorf RA. Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2receptor activation. British Journal of Pharmacology. 2014;171(13):3115-3131. doi:https://doi.org/10.1111/bph.12677
[3.] Capece U, Moffa S, Improta I, Di Giuseppe G, Nista EC, Cefalo CMA, Cinti F, Pontecorvi A, Gasbarrini A, Giaccari A, Mezza T. Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features. Nutrients. 2022 Dec 21;15(1):18. doi: 10.3390/nu15010018. PMID: 36615676; PMCID: PMC9824456.
[4.] Coleman MD, Georgina, Guido. Effects of Lipoic Acid and Dihydrolipoic Acid on Total Erythrocytic Thiols under Conditions of Restricted Glucose in vitro†. Basic & Clinical Pharmacology & Toxicology. 2006;100(2):139-144. doi:https://doi.org/10.1111/j.1742-7843.2006.00025.x
[5.] Cronan JE. Progress in the Enzymology of the Mitochondrial Diseases of Lipoic Acid Requiring Enzymes. Frontiers in Genetics. 2020;11:510. doi:https://doi.org/10.3389/fgene.2020.00510
[6.] El-Hattab AW, Zarante AM, Almannai M, Scaglia F. Therapies for mitochondrial diseases and current clinical trials. Mol Genet Metab. 2017 Nov;122(3):1-9. doi: 10.1016/j.ymgme.2017.09.009. Epub 2017 Sep 18. PMID: 28943110; PMCID: PMC5773113.
[7.] Khan H, Singh TG, Dahiya RS, Abdel-Daim MM. α-Lipoic Acid, an Organosulfur Biomolecule a Novel Therapeutic Agent for Neurodegenerative Disorders: An Mechanistic Perspective. Neurochemical Research. 2022;47(7):1853-1864. doi:https://doi.org/10.1007/s11064-022-03598-w
[8.] Rupa Health. Redox Antioxidant Protection Assay Sample Report.pdf. Google Docs. https://drive.google.com/file/d/1Nvm-8KOPTK2InJyjT8cvdv1m9aaDh6MV/view